UK Committee Attacks Pharma Over Lack Of Medicinal Cannabis Research
The pharmaceutical industry has come under attack by a UK parliament committee for failing to make medicinal cannabis products available for clinical trials, saying that a "robust research base" is needed on which to base future treatment decisions.
You may also be interested in...
New draft guidance from the health technology assessment body NICE says that more evidence is needed on cannabis-based medicines before they can be more widely used. In the meantime, it says they should not be used in chronic pain, epilepsy or spasticity in multiple sclerosis, while nabilone may be used for chemotherapy-related sickness.
Drug Science, a UK charity, is about to launch a 20,000-patient pilot project looking at the use of medicinal cannabis for conditions like chronic pain, multiple sclerosis and Tourette’s syndrome. It says a special licensing status for such products could eventually be possible.
A two-year pilot program in France will look at the practicalities of prescribing medicinal cannabis for patients with one of five specific conditions.